TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3...
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, July 15, 2025 /PRNewswire/ -- BioVaxys...
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //
VANCOUVER, BC, July 15, 2025 /CNW/ -- BioVaxys...
ORLANDO, Fla., July 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy Inc. (OTC: BLEG), a diversified holdings company, today announced significant changes in its leadership structure and a strategic merger initiative aimed at positioning the company for growth in the burgeoning addiction therapeutics sector.
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC).
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International...
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International...
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...